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Adipocytes represent a major cell type in the mammary tumor microenvironment and are important for tumor 
growth. Collagen VI (COL6) is highly expressed in adipose tissue, upregulated in the obese state, and enriched 
in breast cancer lesions and is a stimulator of mammary tumor growth. Here, we have described a cleavage 
product of the COL6α3 chain, endotrophin (ETP), which serves as the major mediator of the COL6-mediated 
tumor effects. ETP augmented fibrosis, angiogenesis, and inflammation through recruitment of macrophages 
and endothelial cells. Moreover, ETP expression was associated with aggressive mammary tumor growth and 
high metastatic growth. These effects were partially mediated through enhanced TGF-β signaling, which con-
tributes to tissue fibrosis and epithelial-mesenchymal transition (EMT) of tumor cells. Our results highlight 
the crucial role of ETP as an obesity-associated factor that promotes tumor growth in the context of adipocyte 
interactions with tumor and stromal cells.
Introduction
Breast cancer is the most common malignancy found in women. 
Among a number of risk factors, obesity ranks high and contributes 
significantly to postmenopausal breast cancer risk (1). Epidemio-
logical evidence supports a tight association among obesity, cancer 
incidence, and mortality (2). Hence, the adipocyte, as a major con-
stituent of the mammary tumor stroma (3), is a likely contributor to 
tumor growth. The interactions between malignant epithelial cancer 
cells and the surrounding stromal cells have a profound impact on 
tumor physiology, including cell growth, survival, metastasis, and 
recurrence (4). Numerous studies have documented contributions 
of stromal cells to tumor growth, through factors released from 
tumor-associated macrophages, fibroblasts, and endothelial cells 
(5–7). However, less is known about adipocyte factors that dominate 
the tumor microenvironment; such factors are either permissive or, 
in some cases, actively contributing to tumor cell growth (8).
The adipocyte is an established endocrine organ, secreting vari-
ous signaling molecules — such as adipokines, chemokines, and 
extracellular matrix (ECM) constituents — in response to nutri-
tional or hormonal stimuli (9). Adipocyte-derived factors involved 
in tumor progression include proteins such as adiponectin, leptin, 
TNF-α, monocyte chemotactic protein–1 (MCP-1), IL-6, and ECM 
components that control tumor cell behavior within the tumor 
microenvironment. Key signaling networks associated with cell pro-
liferation, angiogenesis, inflammation, and apoptosis are activated 
by adipokines; these include PI3K, ERK1/2, STAT3, and NF-κB (10). 
Such pathways are frequently activated in tumor tissues (11).
Collagen type VI (COL6; encoded by Col6a1, Col6a2, and Col6a3) 
is ubiquitously expressed throughout connective tissues, such as 
blood vessels, muscle, lung, and skin. However, adipose tissue (AT) 
is the most abundant source of COL6 (12). COL6 is a large col-
lagenous glycoprotein composed of 3 chains, α1, α2, and α3, that 
are intracellularly assembled from heterotrimeric monomers to 
tetramers (13). Once secreted into the extracellular space, COL6 
tetramers associate into microfibrils. Subsequently, the carboxy-
terminal C5 domain of the α3 chain is proteolytically cleaved 
off from the COL6 microfibrils (14). However, the details of this 
cleavage event and the functional role of the cleavage product, 
the C5 domain, remain unknown, with the exception that the C5 
domain plays an important structural role for COL6 microfibril 
formation (15). Our previous studies have shown that adipocyte-
derived COL6 is a tumor-promoting factor (16) and that COL6-
knockout (Col6a1–/–) mice — in the background of the mammary 
tumor virus–polyoma middle T antigen (MMTV-PyMT) mam-
mary tumor mouse model (referred to herein as PyMT mice; ref. 
17) — exhibit attenuated formation of early hyperplasia and pri-
mary tumor growth (18). Notably, the carboxyterminal domain of 
the COL6α3 chain is stable and highly enriched in human breast 
cancer specimens compared with full-length COL6α3 (18). How-
ever, it remains unknown whether the cleaved C5 fragment of the 
COL6α3 chain, referred to herein as endotrophin (ETP), partici-
pates in mammary tumor progression.
Our studies explored whether ETP regulates tumor cell growth 
and metastasis on its own, independent of other COL6 subunits, 
or the remainder of the COL6α3 chain. It is widely appreciated 
that the ECM provides mechanical and structural support within 
the microenvironment. In addition, ECM-derived proteolytic 
fragments can directly activate various signaling pathways, influ-
encing events in neighboring cells that express ECM receptors, 
such as integrins (19). To better define the role of ETP in tumor 
progression within the local tumor microenvironment, indepen-
dent of the rest of the COL6 complex, we generated transgenic 
mice that harbor ETP with a signal sequence under the control of 
the mammary epithelial specific MMTV promoter. MMTV-ETP 
transgenic mice were characterized either independently (referred 
to herein as ETP mice), in the background of PyMT mice (PyMT/
ETP mice), or with tumor implantations into isogenic mice. We 
used these mouse models in combination with specific ETP neu-
tralizing antibodies to evaluate their therapeutic potential. The 
aim of our studies was to identify and define mechanisms respon-
sible for the effects of COL6 on tumor growth and metastasis 
and further establish which signaling pathways play critical roles 
mediating the potent ETP effects.
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Results
Host-derived COL6 is required to support mammary epithelial cancer cell 
growth. In order to assess the effects of COL6 on mammary tumor 
progression, we determined mammary epithelial cancer cell growth 
in the Col6a1–/– mouse, which lacks a functional COL6A1 chain. 
This leads to the functional deficiency of the holo-COL6 hetero-
trimeric complex (20). The growth of the mouse mammary cancer 
cell line Met-1, originating from a PyMT mouse, was significantly 
attenuated in Col6a1–/– versus WT mice (Figure 1, A and B). Thus, 
the lack of functional COL6 in the tumor microenvironment led to 
a substantial reduction in mammary epithelial cancer cell growth.
ETP is abundant in tumor tissues. To further investigate a role of 
COL6 in tumor progression, particularly in the context of ETP, 
we generated polyclonal antibodies specific for either mouse or 
human ETP domains (Supplemental Figure 1, A and B); a sub-
stantial degree of conservation was preserved between the species 
(Figure 2A). Similar to holo-COL6 levels, secreted ETP was read-
ily identified in conditioned media of 3T3-L1 adipocytes, but not 
3T3-L1 fibroblasts (Figure 2B). Consistent with this observation, 
we observed high ETP levels in the AT of obese animals, such as 
ob/ob and db/db mice, compared with lean controls (Figure 2C). 
Interestingly, ETP prominently accumulated in obesity-associ-
ated crown-like structures of AT (Figure 2C, arrows), prominent 
structures in dysfunctional adipocytes in which infiltrating mac-
rophages mediate chronic inflammatory responses (21). In con-
trast, a holo-COL6–specific antibody primarily highlighted a 
signal at the periphery of adipocytes (Supplemental Figure 2C). 
Immunostaining of tumor tissues from PyMT mice with anti–
holo-COL6 showed that entire tumor lesions were surrounded by 
COL6 fibrils, with weaker staining observed in AT (Figure 2, D and 
G). Interestingly, cleaved soluble ETP freely diffused in the micro-
environment and accumulated on primary tumor lesions of PyMT 
mice in a paracrine manner (Figure 2, E and G). Of note, ETP 
was less prominent on metastasized tumors in the lung (Figure 
2F), which suggests that ETP levels on tumor cells may critically 
depend on the presence of local adipocytes to supply ETP. Histo-
logical analysis of human breast tumor tissues indicated that ETP 
was highly abundant on both epithelial cancer cells and various 
stromal cells within the tumor microenvironment, with a much 
lower signal seen in benign tissues (Figure 3A and Supplemental 
Figure 2A). In the mouse, ETP was highly expressed in the mam-
mary epithelial cancer cell Met-1, relative to other cell types, such 
as the endothelial cell line MS-1 or primary macrophages (Supple-
mental Figure 2D). This suggests that cancer cells can express ETP, 
even though AT was the major source for COL6 among various 
WT tissues and PyMT tumor tissue (Supplemental Figure 2, E and 
F). ETP overexpression was not restricted to mammary cancer cells. 
We observed similar increases in ETP in other tumor sections, such 
as in human colon cancers, which showed significantly higher ETP 
levels than those in benign tissues (Figure 3B and Supplemental 
Figure 2B). ETP may therefore be a relevant player in several other 
tumor settings and may play a crucial role in cancer cell behavior 
through both paracrine and autocrine signaling.
To identify the tissues that are critical targets for ETP in cir-
culation, we injected infrared fluorescent dye–labeled (IRD-800) 
recombinant ETP protein into PyMT mice through tail vein injec-
tion. The signal distribution in these tumor-bearing mice was 
compared with that of WT mice. The in vivo fate of the labeled 
ETP was monitored by fluorescence scanning. A high fluorescence 
signal was observed in liver and bladder of all mice due to clear-
ance. However, ETP was predominantly observed in tumor lesions 
compared with control-labeled IgGs (Figure 3C). As determined 
by quantification, ETP was highly enriched in mammary tumor 
tissues relative to mammary glands of WT mice (Figure 3D).
Elevated local ETP levels convey higher antiapoptotic and promitotic 
indices in normal mammary epithelial cells. To directly explore the role 
of ETP in mammary tumor growth, we used a gain-of-function 
approach with a transgenic mouse model expressing ETP under 
the control of MMTV promoter to elevate local ETP levels within 
the mammary gland. To achieve efficient ETP secretion, a prolac-
tin signal sequence was inserted in-frame 5′ to the region encoding 
the mouse ETP sequence (Supplemental Figure 3A). ETP transgene 
levels were highly upregulated in a high-expressing line compared 
with the more modest overproduction of other low-expressing 
lines (Supplemental Figure 3B). Immunostaining with antibodies 
against ETP indicated that ETP was enriched in mammary ductal 
epithelium in both transgenic mouse lines relative to WT, whereas 
no ETP signal was detected in Col6a1–/– mice (Figure 4A).
Assessment of mammary gland development in ETP mice is crit-
ical to evaluate the roles of ETP in mammary tumor progression, 
as most primary mammary tumors originate from mammary duc-
tal or intraductal epithelial cells. Histological analysis — includ-
ing whole-mount, H&E, and Masson’s Trichrome C staining — of 
mammary glands showed that ductal epithelial growth and the 
degree of fibrosis in both ETP transgenic lines was comparable to 
those in WT mice (Supplemental Figure 3, C–E). The final stages 
of mammary gland development are completed upon pregnan-
cy, lactation, and involution (22). The high-expressing ETP line 
displayed a deficiency in fertility (Supplemental Figure 3F) and 
reduced locomotion (data not shown); these secondary effects 
of elevated ETP levels may make the interpretation of local find-
ings within the mammary gland more challenging. We therefore 
focused on the low-expressing line and examined the process of 
involution. In this process, the secretory epithelial cells undergo 
apoptosis with concomitant redifferentiation of adipocytes, there-
by reconstituting prepregnancy status after weaning. Involution 
was delayed at an early stage of the process in ETP mice (Supple-
mental Figure 3G), along with a reduction in apoptosis in secre-
tory epithelial cells (Figure 4, B and C). This suggests that ETP 
Figure 1
Regression of tumor growth in Col6a1–/– mice. Met-1 cells (0.5 × 106 
cells/mouse) were implanted into either FVB WT or Col6a1–/– 
(COL6KO) mice (mean ± SEM; n = 5 per group). (A) Tumor volume, 
determined by caliper measurements. ***P < 0.001 vs. WT, 2-way 
ANOVA. (B) Tumor weight. **P = 0.0022 vs. WT, unpaired t test.
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acts as a potent antiapoptotic factor in this setting. Delays in the 
process of involution frequently resemble the prolonged survival 
of epithelial cells in a cancer setting. As a comparison, we observed 
an enhanced rate of involution in Col6a1–/– mice (Supplemental 
Figure 3G); concomitantly, apoptosis was increased approximate-
ly 2-fold in Col6a1–/– mice (Figure 4, B and C). Nevertheless, ETP 
mice did eventually revert back to prepregnancy status, albeit with 
delayed kinetics (Supplemental Figure 3G).
Abnormal developmental cues can induce and promote a cancer-
ous transformation of mammary epithelial cells. Indeed, several 
mice with high ETP expression spontaneously developed tumors 
(Figure 4D). We did not observe spontaneous tumor formation in 
low ETP expressers or WT mice up to 18 months of age (data not 
shown). Immunostaining with Ki67 showed that cell proliferation 
was increased in hyperplastic lesions of mammary tissue in the high-
expressing mice (Figure 4E), which suggests that high levels of ETP 
alone are sufficient to augment promitogenic activity. No lesions 
were observed in WT mice, and hence no detectable mitogenic 
activity or Ki67 signal was evident (Figure 4E). We therefore direct-
ed further efforts toward the physiologically more relevant lower-
expressing ETP line, since these mice develop the mammary ductal 
epithelium completely normally and overexpress ETP only locally.
ETP augments tumor growth and metastasis in PyMT mice. To assess 
ETP function, we aimed to expose ETP mice to an additional 
tumorigenic trigger. For this purpose, we used the PyMT mouse, 
an aggressive mammary adenocarcinoma model that develops late-
stage carcinoma and pulmonary metastasis within 15 weeks (23). 
Accumulated ETP levels in tumor tissues of PyMT/ETP mice were 
about 1.5-fold those of endogenous ETP in PyMT mice (Figure 5A), 
and the rate of early tumor growth was augmented in PyMT/ETP 
versus PyMT mice (Figure 5B). In light of high endogenous ETP 
levels accumulating locally as well, differences in late-stage tumors 
were not significant between the 2 groups when assayed by caliper 
measurements (Figure 5C). More striking differences were obtained 
at the level of metastasis (Figure 5, D and E). To more sensitively 
assess tumor growth, we generated a mouse model harboring the 
Figure 2
Expression profiles of ETP. (A) COL6 is composed of COL6α1, -α2, and -α3 chains. The C5 domain of the α3 chain, cleaved off the COL6 micro-
filament, is highlighted in red. Shown are amino acid sequences compared between the human and mouse COL6α3-C5 domain. Conserved 
sequences are highlighted in yellow. (B) Western blots showing abundant secretion of ETP from adipocytes. Conditioned media from 3T3-L1 
preadipocytes and fully differentiated adipocytes were subjected to Western blotting using α-mETP and α-COL6. Arrows indicate the secreted 
form of ETP. (C) ETP immunostaining of mammary gland tissues from obese animals, ob/ob and db/db mice, compared with lean controls 
(n = 5 per group). Arrows indicate crown structure. Scale bars: 50 μm. (D and E) holo-COL6 and ETP immunostaining of tumor tissues from 
9-week-old PyMT mice with α-COL6 (D) and α-mETP antibody (E), respectively. Lung tissues from 13-week-old PyMT mice were used for metas-
tasized tumor lesions (F). Scale bars: 50 μm. (G) α-COL6– and α-ETP–positive staining area in tumor or stroma for the primary tumors. Data are 
mean ± SEM of multiple fields in n = 5 per group. ***P < 0.001 vs. tumor, unpaired t test.
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infrared fluorescence transgene FP635 under the control of the 
MMTV promoter, which allowed us to monitor tumor growth 
longitudinally through in vivo imaging (Supplemental Figure 4A). 
Breeding this transgene into PyMT animals (referred to herein as 
FP635/PyMT mice) allowed us to readily assess tumor growth by 
whole-body fluorescence signal intensity, given that the infrared 
range allows deeper tissue penetration with reduced autofluores-
cence from surrounding AT (Supplemental Figure 4B). By assess-
ing in vivo images, the differences of tumor burden between the 
FP635/PyMT/ETP and FP635/PyMT groups became apparent and 
significant (Figure 5F), which indicates that ETP not only promotes 
pulmonary metastasis, but also further enhances primary tumor 
growth. Ki67 staining at late stages did not show an increased fre-
quency of proliferating cells in tumor tissues in PyMT/ETP versus 
PyMT animals (Figure 6A). Nevertheless, tumor tissue fibrosis at 
that age was doubled in PyMT/ETP versus PyMT mice (Figure 6B). 
Indeed, a subset of genes associated with tissue fibrosis, including 
several types of collagens, lysyl oxidase (Lox), and TGFβ, as well as 
genes for epithelial-mesenchymal transition (EMT), such as fibro-
blast stimulating protein (FSP1) and vimentin, showed trends 
toward an increase in tumor tissues (Figure 6, E and F). More dra-
matic alterations were obtained in the area of tumor angiogenesis: 
ETP tumor tissues harbored a 3-fold increase in functional blood 
vessel area compared with controls (Figure 6C), with a concomi-
tant reduction in hypoxia (Figure 6D). Markers for angiogenesis, 
such as CD31, VEGFR2, and HIF1α, were significantly upregulated 
in tumor tissues from PyMT/ETP mice. Moderate increases were 
observed in lymphangiogenesis markers, such as VEGFc, podo-
planin (Pdpn), and the lymphatic vessel endothelial hyaluronan 
receptor (LYVE-1) (Figure 6G). These gene expression changes were 
consistent with the immunostains of tumor tissues for lymphan-
giogenesis, such as podoplanin (Figure 6C). Levels of inflammatory 
cytokines, such as IL6 and TNFα, were moderately increased (Fig-
ure 6H). Taken together, these findings indicate that ETP enhances 
fibrosis, angiogenesis, and inflammation, all of which are known to 
promote primary tumor growth and metastasis (24).
ETP enhances the EMT process. To investigate gene expression 
alterations induced by ETP, we compared cDNA microarrays 
from size-adjusted tumor tissues from PyMT/ETP and PyMT 
mice. ETP-modulated genes fell primarily into categories of tar-
gets involved in key phosphorylation events, such as phospha-
tases, kinases, and other phosphoproteins (Supplemental Figure 
5A). Furthermore, the most significantly altered canonical path-
ways modulated by ETP were associated with immune responses, 
cell cycle regulation, and stem cell pluripotency (Supplemental 
Figure 5B). Notably, stem cell–like pluripotency is a hallmark 
of cancer cells for survival and invasion, which is tightly linked 
to the process of EMT (24). Levels of the epithelial cell mark-
er E-cadherin — the loss of which is a characteristic feature of 
EMT (25) — were significantly decreased in tumor tissues from 
PyMT/ETP relative to PyMT mice (Figure 7A), which suggests 
that ETP induces EMT. This enhanced EMT was consistent with 
the in vivo phenotype: the metastatic burden was prominently 
increased in PyMT/ETP versus PyMT mice (Figure 5, D–F).
Figure 3
ETP levels in human cancer specimens and its target tissues. (A and B) Human cancer tissues compared with those of benign tissues were 
immunostained with human ETP–specific polyclonal antibody. Human samples for breast cancer (A) and colon cancer (B) were analyzed. Scale 
bars: 25 μm. (C and D) Whole body in vivo imaging of injected ETP. IRD-800 fluorescence–labeled ETP protein (10 μg) was intravenously injected 
into WT, 8-week-old PyMT, and 10-week-old PyMT mice by tail vein. (C) ETP levels were visualized by the Licor Infrared Scanner 10–90 minutes 
after injection. Arrows indicate mammary tumors. L, liver; B, bladder; T, tumor. IgG was used as a negative control. (D) Tissues were excised 2 
hours after injection, and ETP-positive fluorescence signals were determined with a Licor Infrared Scanner. Quantified values were normalized 
to total area and represented as percentage of WT. ***P < 0.001.
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Effects of ETP synergize with the canonical TGF-β pathway to promote lung 
metastasis. To delineate the mechanism underlying the increase in 
EMT processes in PyMT/ETP mice, we investigated the effects of ETP 
on the TGF-β pathway. TGF-β signaling has previously been impli-
cated in EMT-associated tumor growth and metastasis, which are 
associated with the acquisition of metastatic traits (26). To examine 
whether ETP signaling converges with the canonical TGF-β pathway, 
we generated 2 ETP constructs: a form that was secretion incom-
petent, and thus retained within the secretory pathway, as well as a 
secreted form (Supplemental Figure 6A). We used these constructs 
for a reporter assay with TGF-β–dependent Smad protein–binding 
elements (SBEs) (27). Interestingly, only the secreted form of ETP 
enhanced SBE reporter activity; furthermore, this was critically depen-
dent on TGF-β stimulation (Figure 7B), which indicates that ETP 
synergizes with the TGF-β pathway through cell-surface interactions. 
This is based on the fact that the enhanced TGF-β signaling synergis-
tically activated through ETP was completely abolished by treatment 
with the monoclonal TGF-β neutralizing antibody 1D11 (Figure 7C), 
which strongly suggests that ETP-dependent SBE reporter activation 
and consequent signaling events fully rely on the presence of TGF-β.
To further elucidate the TGF-β–dependent role of ETP as a tumor 
enhancer, in a less aggressive experimental setting of tumor pro-
gression, we used an allograft model in which we inhibited TGF-β 
signaling with TGF-β neutralizing antibodies in the context of ETP 
overexpression. Although tumor growth for Met-1 cells was sig-
nificantly enhanced by ETP, TGF-β inhibition did not efficiently 
reduce ETP-induced tumor growth (Figure 7D), which suggests that 
TGF-β–mediated signaling is less relevant for the growth of primary 
tumors in the ETP-expressing tumor stroma. Histological analysis 
of tumor tissues revealed an increase in mesenchymal-like stromal 
cells in the ETP-expressing tumor stroma, a phenomenon that was 
reversed by TGF-β inhibition (Figure 7E). This further suggests that 
the TGF-β pathway participates in ETP-induced EMT. Addition-
ally, the ETP-mediated increase in tissue fibrosis was attenuated by 
TGF-β inhibition (Figure 7F). These results were subsequently con-
firmed by examining EMT markers in tumor tissues (Figure 7G), 
namely E-cadherin, vimentin, and α-SMA, which is an activated 
myofibroblast marker widely used for EMT assessment (6). Of note, 
manipulation of TGF-β signals in tumor tissues using genetic mouse 
models for TGF-β, TGF-βR1, and TGF-βRII (28–30) have highlight-
Figure 4
Transgenic mice expressing ETP under the MMTV promoter. (A) ETP immunostaining showing strong ETP positive signal in mammary ductal 
epithelium in the transgenic mice lines (ETP low and high), but not WT and Col6a1–/– mice. Scale bars: 50 μm. (B and C) Antiapoptotic effects 
of ETP. (B) Apoptosis for mammary epithelial cells during involution was determined by TUNEL assay on mammary glands of WT, ETP, and 
Col6a1–/– mice 2 days after forced weaning. Arrows indicate TUNEL-positive apoptotic cells. Scale bars: 50 μm. (C) Quantification of TUNEL-
positive cells, represented as mean ± SEM (multiple images, n = 3 per group). ***P < 0.001, *P < 0.05 vs. WT, unpaired t test. (D and E) Promitotic 
effects of ETP. High ETP expressers (32 weeks old) spontaneously developed tumors. (D) Whole body image (left; arrows indicate tumors) and 
H&E staining of mammary gland (middle) and lung (right) tissue. Boxed regions are shown at higher magnification below. Scale bars: 200 μm. (E) 
Cell proliferation was determined by Ki67 staining with mammary glands of 32-week-old ETP high-expressing and WT mice. Scale bars: 50 μm.
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ed that TGF-β signaling augments cancer cell invasiveness, primarily 
through stimulation of EMT processes, enhancing metastatic rather 
than primary tumor growth. We subsequently investigated the effi-
cacy of TGF-β neutralizing antibodies on the metastatic potential of 
cancer cells from PyMT/ETP and PyMT mice (referred to herein as 
ETP+- and Ctrl-cancer cells, respectively). ETP+-cancer cells metasta-
sized at a higher rate than Ctrl-cancer cells (Figure 7H). Moreover, 
this increased rate of metastasis was attenuated by TGF-β inhibi-
Figure 5
ETP augments primary tumor growth and pulmonary metastasis in the background of PyMT mice. (A) ETP immunostaining, with a high ETP-
positive signal in tumor tissues from 12-week-old PyMT and PyMT/ETP mice. Scale bars: 50 μm. Intensity of ETP staining was quantified and 
represented as mean ± SEM (n = 5 per group). *P = 0.02 vs. PyMT, unpaired t test. (B) Whole-mount staining of mammary gland tissues from 
8-week-old PyMT and PyMT/ETP mice, with early neoplastic lesion areas increased by ETP. (C) Tumor volume was determined by weekly cali-
per measurements from PyMT (n = 35) and PyMT/ETP (n = 38) mice. Results are represented as mean ± SEM. P = NS, 2-way ANOVA. (D and 
E) ETP augmented pulmonary metastasis. (D) Pulmonary metastatic growth was determined by measuring the tumor incidence in lung tissues 
(8- to 17-week-old, n = 22–25 per group). H&E-stained preparations for lung tissues were used for analysis. Shown is percent metastasis-free 
mice over time. *P = 0.025, log-rank test. (E) Representative H&E stain for lung tissues showing the degree of pulmonary metastasis in 15- and 
17-week-old PyMT and PyMT/ETP mice. (F) Representative whole-body images for tumor burden. Tumor volume for 13-week-old FP635/PyMT 
and FP635/PyMT/ETP mice was monitored by IVIS fluorescence scanner. Metastatic burden was determined by fluorescence signals in lung 
tissues. Quantified results are represented as mean ± SEM (n = 8–9 per group). *P = 0.0117, **P = 0.0011 vs. PyMT, unpaired t test.
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tion (Figure 7H). Collectively, these results suggest that the TGF-β–
dependent aspects of ETP action relate only to the acquisition of can-
cer cell invasive and metastatic traits, not to primary tumor growth.
Reconstitution of ETP into Col6a1–/–-cancer cells augments tumor 
growth, with higher tissue fibrosis and EMT. We determined that Met-1 
cells did not grow in a Col6a1–/– host (Figure 1). Furthermore, 
allografts of Col6a1–/–-cancer cells (isolated from tumor tissues 
of PyMT/Col6a1–/– mice) implanted into isogenic WT mice failed 
to thrive (Figure 8A). To determine whether ETP can restore the 
blunted tumor growth of Col6a1–/–-cancer cells, the growth rate 
of Col6a1–/–/ETP cells (isolated from PyMT/Col6a1–/–/ETP mice, 
in which ETP was reconstituted into the PyMT/Col6a1–/– back-
ground) was analyzed and compared with Ctrl- or Col6a1–/–-can-
cer cells. Tumor growth and tumor weight were significantly 
increased with Col6a1–/–/ETP versus Col6a1–/– cells (Figure 8, 
A–C). Even though ETP reconstitution rescued tumor growth of 
Col6a1–/–-cancer cells, tumors remained smaller in size than those 
obtained with Ctrl-cancer cells (Figure 8, A–C). This suggests that 
ETP alone is not sufficient to completely reconstitute growth of 
Col6a1–/–-cancer cells. However, a number of important aspects 
were reproduced with ETP reconstitution. Significant ETP-
induced changes in Col6a1–/–-cancer cells included tissue fibrosis 
as well as an enhanced EMT process (Figure 8, D–G). Notably, the 
FSP-1+ fibroblast population was not responsive to ETP (Figure 
8H), which suggests that the ETP response is cell type specific.
ETP, as a potent chemokine, augments primary tumor growth through 
tumor-stromal interactions. To examine cancer cell–autonomous effects, 
we performed allografts without Matrigel plugs. Tumor growth of 
ETP+-cancer cells was comparable to Ctrl-cancer cells (Supplemental 
Figure 7A). Indeed, in vitro examination of mammary cancer cells, 
including Met-1 and MCF-7 cells, revealed that cell proliferation was 
not affected by addition of purified ETP (Supplemental Figure 7, B 
Figure 6
Histological analysis for tumor tissues of PyMT/ETP versus PyMT mice. (A) Proliferation indices were determined by immunostaining with Ki67. 
Quantified results represent mean ± SEM (n = 5 per group). P = NS vs. PyMT, unpaired t test. (B) Fibrosis indices were determined by Mas-
son’s Trichrome C stain. Percent fibrotic area over the tumor lesions was quantified. Data represent mean ± SEM (n = 5 per group). **P = 0.01 
vs. PyMT, unpaired t test. Arrows indicate collagen fibrils. (C) Functional blood vessel areas were determined by lectin perfusion. Podoplanin 
(lymphangiogenesis marker) and DAPI (nucleus) were costained. Quantified results represent mean ± SEM (n = 5 per group). **P = 0.003 
vs. PyMT, unpaired t test. (D) Hypoxia was determined by pimonidazole-HCl injection. Hypoxic lesions were stained in dark brown. Quantified 
results represent mean ± SEM (n = 5 per group). ***P = 0.0007 vs. PyMT, unpaired t test. (E–H) Total RNA was prepared from the tumor tissues 
from PyMT/ETP and PyMT mice. mRNA levels for the genes responsible for fibrosis and EMT (E and F), angiogenesis and lymphangiogenesis 
(G), and inflammation (H) were determined by qRT-PCR. mRNA levels were normalized with β-actin and represented as mean ± SEM (n = 8 per 
group). Relative values of each gene are represented as fold change relative to PyMT. *P < 0.05, ***P < 0.001 vs. PyMT, 2-way ANOVA. Scale 
bars: 50 μm (A–C); 100 μm (D). Insets in A are enlarged ×5.
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Figure 7
ETP augments metastasis through enforcing TGF-β–dependent EMT. (A) E-cadherin immunostaining for tumor tissues from PyMT and PyMT/
ETP. (B and C) SBE-luciferase reporter assay. See Supplemental Methods for details. Data represent fold increase (3 independent experiments). 
**P < 0.01, *P < 0.05, 2-way ANOVA. pRA-ctrl, empty; pRA-sETP, secretion form; pRA-ETP, intracellular form. (D–G) Allografts of Met-1 cells in the 
presence of either ETP (20 ng/plug) or PBS mixed with 1D11 or IgG (10 μg/plug) within a Matrigel plug. 10 days after implantation, additional 1D11 
or IgG (100 μg) was i.p. injected once a week during tumor progression. (D) Tumor volumes represent means ± SEM (n = 5 per group). *P < 0.05, 
2-way ANOVA. (E) H&E staining. The ratio of stromal area in tumor tissues was quantified. Data represent mean ± SEM (n = 5 per group). *P < 0.05, 
unpaired t test. T; tumor and S; stroma. (F) Fibrosis was determined by Masson’s Trichrome C stain. Data represent mean ± SEM (n = 5 per group). 
**P < 0.01, ***P < 0.001, unpaired t test. (G) Western blotting for EMT markers E-cadherin, vimentin, and α-SMA. β-actin, loading control. Data 
represent fold increase (n = 5 per group). *P < 0.05, **P < 0.01, ***P < 0.001, unpaired t test. (H) Control and ETP+-cancer cells were isolated from 
FP635/PyMT and FP635/PyMT/ETP mice and conveyed into WT mice by tail vein injection (0.5 × 106 cells/mouse). Either IgG or 1D11 (100 μg) 
was i.p. injected every 5 days. 20 days post injection, metastasized cancer cells in the lung tissues were determined by fluorescence intensity. Data 
represent fold increase (n = 3–4 per group). **P < 0.01, *P < 0.05, unpaired t test. Scale bars: 20 μm (A); 50 μm (E); 100 μm (F).
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and C). However, the vascularization of allografts of ETP+-cancer 
cells was significantly increased (Supplemental Figure 7D). This sug-
gests that cancer cells per se are not responsive to ETP with respect to 
growth, but that ETP augments endothelium formation; therefore, 
tumor stromal, rather than cancer cell–autonomous, interactions 
account for the increase in tumor growth observed in vivo. To test 
this, ETP+- and Ctrl-tumors were implanted into isogenic WT mice. 
ETP+-tumors grew dramatically faster than did Ctrl-tumors (Figure 
9A). From these allograft studies, the potent proangiogenic, profi-
brotic, and proinflammatory effects of ETP, initially observed in the 
PyMT setting (Figure 6), became evident (Supplemental Figure 8). In 
light of this, we focused on stromal effects on primary tumor growth. 
These stromal effects were mediated by the tumor-associated vascu-
lature, as well as fibrotic and inflammatory pathways. Major stromal 
target cell types involved in tumor interactions were endothelial cells, 
fibroblasts, and macrophages, all of which have established roles in 
tumor growth and metastasis (31).
In light of the findings above, we hypothesized that ETP 
functions as a chemokine during tumor stroma expansion, 
recruiting or possibly activating stromal cells to support tumor 
growth. In vivo targeted cell recruitment studies revealed that 
Matrigel plugs combined with recombinant ETP and injected 
into mammary fat pads of WT mice recruited significantly more 
stromal cells than did PBS (Figure 9B). We subsequently gener-
ated monoclonal anti-ETP antibodies to effectively neutralize 
ETP, thereby generating an ETP-based therapeutic approach 
Figure 8
ETP reconstitution into Col6a1–/–-cancer cells rescues tumor growth. Cancer cells isolated from PyMT, PyMT/Col6a1–/–, and PyMT/Col6a1–/–/
ETP mice were mixed with the same volume of Matrigel (50 μl) and implanted into WT mice (0.5 × 106 cells/mouse). (A) Tumor growth 
(mean ± SEM; n = 5–8 per group), determined by caliper measurements. *P = 0.024 vs. Col6a1–/–, unpaired t test. (B) Representative image 
35 days after implantation. (C) Tumor weight (mean ± SEM; n = 5–8 per group). *P = 0.023 vs. Col6a1–/–, unpaired t test. (D–H) Tissue 
fibrosis was determined by Masson’s Trichrome C stain (D), and EMT was determined by immunostaining for E-cadherin (E), vimentin (F), 
α-SMA (G), and FSP-1 (H). Cytokeratin (epithelial cells) and DAPI (nucleus) were costained in G and H. Positive staining areas were quan-
tified and represented as fold increase over Ctrl-tumors (multiple images, n = 5 per group). *P < 0.05, ***P < 0.001 vs. Col6a1–/–, unpaired 
t test. Scale bars: 50 μm (E and F); 100 μm (D, G, and H).
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PyMT/ETP, PyMT/Col6a1–/–, and PyMT/Col6a1–/–/ETP mice 
for their chemoattractive potential. More specifically, mam-
mary epithelial cancer cells were cocultured with either mouse 
endothelial cells (MS-1; Figure 9, D–G) or primary macrophages 
(Figure 9, H–K) in a Transwell plate (Figure 9C), and the migra-
tion of the MS-1 cells and macrophages were subsequently 
quantified (Figure 9L). ETP+-cancer cells recruited substantially 
(Supplemental Figure 1C). Chemokine activity of ETP was com-
pletely blocked by 10B6, but not by 1D11 (Figure 9B), which 
suggests that ETP-inherent chemokine activity was independent 
of TGF-β signaling. Furthermore, the majority of cells recruited 
into the Matrigel plugs by ETP were CD31+ endothelial cells 
(Supplemental Figure 9A). Similarly, we analyzed primary mam-
mary epithelial cancer cells isolated from tumor tissues of PyMT, 
Figure 9
ETP acts as a chemokine augmenting tumor growth. (A) Tumor growth significantly increased in ETP+-tumor tissue allograft into WT mice. Tumor 
volume was determined 1 month after implantation (representative images). Data represent mean ± SEM (n = 5 per group). ***P < 0.001, unpaired 
t test. (B) In vivo Matrigel bioassay. Matrigel (50 μl) was mixed with ETP (100 ng/plug) or PBS and implanted into WT mice in the presence of 
IgG, 1D11, or 10B6 (20 μg/plug). 2 days after implantation, plugs were excised and stained for H&E. Scale bars: 100 μm. (C–L) Cancer cells were 
plated in the bottom chamber 1 day prior to seeding MS-1 cells (5 × 105 cells/well) and macrophages (1 × 105 cells/well) atop the membrane 
chamber in Transwell and incubated for 18–24 hours (C). (D–K) Representative images of multiple independent experiments. Scale bars: 100 μm. 
(L) Quantitation (mean ± SEM; n = 3 per group). ***P < 0.001, **P < 0.05, *P < 0.01, unpaired t test. (M) MS-1 migration assay. MS-1 cells (5 × 105 
cells/well) were plated atop the chamber in Transwell and incubated for 24 hours. Chemotaxis was set up by following cell migration from DMEM/
serum-free to DMEM/2% FBS/PBS or DMEM/2% FBS/ETP protein (1 μg/well). Images are representative of multiple independent experiments. 
Data represent mean ± SEM (n = 3 per group). ***P = 0.008, unpaired t test. Scale bars: 100 μm.
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In vitro cell migration assays revealed that ETP recruited twice 
as many MS-1 cells than did controls (Figure 9M). Furthermore, 
in vitro angiogenesis assays using MS-1 cells demonstrated that 
endothelial cells incubated with conditioned media from ETP-
overexpressing HEK-293T cells mobilized and organized vascu-
lature structures much more actively than conditioned medium 
harvested from control HEK-293T cells (Supplemental Figure 
more endothelial cells and macrophages (Figure 9, E, I, and L). 
This effect was not observed in Col6a1–/–-cancer cells (Figure 9, 
F, J and L). More importantly, ETP reconstitution into Col6a1–/–
-cancer cells completely recovered their chemoattractant prop-
erties (Figure 9, G, K, and L), to a level comparable with ETP+-
cancer cells. This suggests that the majority of chemoattractant 
properties exerted by COL6 are exerted by ETP.
Figure 10
10B6 blocks ETP-mediated stromal expansion in vivo. (A) 10B6 (200 μg/mouse) was i.p. injected twice weekly into PyMT mice from 9 to 13 weeks 
of age. Tumor growth (mean ± SEM; n = 4–6 per group) was determined by weekly caliper measurements. *P < 0.05, **P < 0.01, ***P < 0.001 
vs. IgG control, 2-way ANOVA. (B) Primary mammary epithelial cancer cells were isolated from 12-week-old FP635/PyMT and FP635/PyMT/
ETP mice and implanted into WT recipients with the same volume of Matrigel. For the 10B6 group, 10B6 was added in a Matrigel plug (10 μg/
plug) admixed with ETP+-cancer cells (i.e., ETP+/10B6). A representative whole-body image was acquired 25 days after implantation using IVIS 
fluorescence scanner. Artificial color indicates fluorescence signal intensity accounts for tumor volume (AU). Quantitative results are represented 
as mean ± SEM (n = 3 per group). *P < 0.05, unpaired t test. (C–I) 6 weeks after implantation, tumor tissues were excised from Ctrl-, ETP+-, and 
ETP+/10B6-cancer cells allografted mice and stained for H&E (C), Masson’s Trichrome C (D), α-SMA (E), FSP-1 (F), CD31 (G), F4/80 (H), and 
Ki67 (I). Quantified results in D–I are mean ± SEM (multiple images, n = 3 per group). *P < 0.05, **P < 0.01, unpaired t test. Scale bars: 50 μm. 
(J) Working model for ETP in mammary tumor progression.
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ing the specific effects of COL6 on tumor behavior have not fully 
been elucidated. Here, we have highlighted that ETP, a cleaved 
product of COL6, is likely to be a critical mediator of several 
tumor-associated phenomena and is of particular importance in 
tumor progression in the context of obesity.
Within the tumor milieu, EMT is initiated by extracellular stim-
uli. This can be exerted by ECM components (collagens, fibro-
nectin, hyaluronic acids, and MMPs) as well as by certain growth 
factors (TGF-β, EGF, and HGF), all of which are provided by both 
paracrine and autocrine signals within the tumor microenviron-
ment (25). One of the prominent ECM molecules released from 
stromal adipocytes is COL6. As a COL6 processing product, ETP 
plays an important role in the local microenvironment, stimulat-
ing TGF-β–dependent EMT in the context of mammary tumors 
to potentiate prometastatic effects (Figure 7). Gene expression 
profiling and immunostaining of tumor tissues from PyMT/ETP 
mice confirmed enhanced ETP-mediated acquisition of EMT 
characteristics, whereas in vitro data indicated that ETP alone 
did not induce EMT (data not shown). This suggests that ETP 
may function as an important costimulator of existing pathways 
for the EMT, such as TGF-β signaling and possibly activation of 
integrins and Wnt signals.
Increased tissue fibrosis, combined with high tissue rigidity (due 
to ECM remodeling and crosslinking), is positively associated with 
tumor growth (39). Our results revealed an ETP-induced fibrotic 
environment, with high levels of myofibroblast accumulation 
within tumor tissues, as a key characteristic of ETP action. These 
activated myofibroblasts in ETP+-tumors were derived, at least in 
part, by EMT. However, we cannot rule out that ETP may facilitate 
additional processes, such as microfibril assembly of preexisting 
collagen fibers (15) or stimulation of myofibroblast differentiation 
(40). Moreover, promoting transformed mesenchymal cell prolif-
eration can enhance the appearance of additional stromal cells (41); 
ETP may also effectively promote this process. Indeed, blocking the 
EMT by using a TGF-β neutralizing antibody did not completely 
eliminate fibrosis in ETP+-tumors (Figure 7F). These data indi-
cate that the ETP-induced EMT and subsequent fibrotic traits in 
tumors contribute to an increase in tumor growth and metastasis, 
which highlights a central role for ETP in tumor progression.
We have also provided evidence for the potent ETP-mediated 
chemoattractant properties. These ETP effects can even be mim-
icked in a tumor-free environment. A number of reports highlight 
significant correlations between COL6α3 and chronic inflamma-
tion, based on increased macrophage infiltration into AT depots 
of obese subjects (42, 43). We propose that the ETP-mediated 
chemoattractant properties described herein may offer a mecha-
nistic basis for these clinical correlations. Neutralizing these ETP-
mediated effects in normal, tumor-free AT may yield beneficial 
outcomes as well. Our current efforts are directed toward adipo-
cyte-derived overexpression of ETP, which will answer the ques-
tion of whether a local excess of ETP will exert beneficial effects 
(due to its proangiogenic properties) or negative effects (due to 
its proinflammatory and profibrotic properties) on a fat pad not 
challenged with an invading tumor.
We have limited insights into the stepwise process that leads 
to cleavage of ETP from its parent molecule. We do not know 
which proteases are involved, or from where they originate. Fibro-
sis in obese AT is associated with an increase of various MMPs or 
TIMPs resulting in collagen degradation (44). MMP-11, MMP-2, 
and MMP-9 have been suggested as peptidase for COL6 (45, 46), 
9B). 10B6 completely blocked these effects (Supplemental Figure 
9B). Thus, ETP plays a crucial role in endothelial cell recruitment, 
migration, and vessel formation during the process of angiogen-
esis. Based on these observations, we conclude that ETP is critical 
for the recruitment of stromal cells into the tumor microenviron-
ment through its action as a chemokine.
A neutralizing anti-ETP monoclonal antibody attenuates tumor 
growth by inhibiting ETP-mediated expansion of the tumor stroma. We 
next examined whether ETP neutralization can attenuate tumor 
progression. Of note, PyMT mice expressed high levels of endog-
enous ETP in the tumor-infiltrated stromal compartment (Fig-
ure 2E). Tumor growth was significantly attenuated by 10B6 
treatment compared with isotype control IgG treatment (Figure 
10A). Similarly, FP635/ETP+-cancer cells were implanted into WT 
mice, with or without 10B6 added to the Matrigel plug; tumor 
growth was then monitored using fluorescence imaging. The 
rate of ETP+-cancer cell growth was significantly higher relative 
to Ctrl-cancer cells; however, their growth was effectively attenu-
ated by 10B6 (Figure 10B). Histological analysis of tumor tissues 
indicated that various stromal cells had the capacity to infiltrate 
into the Matrigel plugs containing ETP+-cancer cells. Again, 10B6 
inhibited ETP-mediated tumor stromal expansion and eventu-
ally triggered tumor regression (Figure 10C). ETP+-cancer cell 
allografts consistently displayed higher levels of fibrosis (Figure 
10D) and a high degree of stromal cell infiltration, including by 
α-SMA+ cells, FSP-1+ fibroblasts, and CD31+ endothelial cells in 
addition to F4/80+ macrophages (Figure 10, E–H). These cells 
were highly proliferative, as demonstrated by Ki67+ staining (Fig-
ure 10I). As expected, the ETP-mediated increase in fibrosis and 
stromal expansion was completely blocked by 10B6 (Figure 10, 
D–H). Collectively, our results indicated that stromal adipocytes 
play a crucial role in mammary tumor progression; that ETP is a 
powerful stromal factor that exerts a major influence on primary 
tumors through its chemokine activities; and that ETP can affect 
metastatic growth via TGF-β–mediated EMT. Thus, ETP-directed 
approaches may serve as novel therapeutic regimens in the treat-
ment of breast cancer (Figure 10J).
Discussion
A prominent environmental stimulus of tumor dissemination 
is hypoxia, triggered by a high demand for cell proliferation and 
insufficient angiogenesis. Comparable to this process, hypertro-
phic AT expansion during obesity can also trigger local hypoxia 
(32) that can further progress to AT fibrosis (33). These obesity-
related pathophysiological changes can lead to an environment 
that is conducive to cancer growth, such as chronic inflamma-
tion, inadequate angiogenesis, and enhanced fibrosis (8). In this 
setting, obesity may contribute to an ETP-rich tumor microen-
vironment through a positive feed-forward mechanism. Indeed, 
COL6α3 message levels are upregulated in obese AT (34). COL6 
upregulation has been reported in various aspects of tumor pro-
gression. Malignant cancer cells can also express COL6; this has 
been reported for the mammary gland (18), the colon (35, 36), 
pancreatic ductal adenocarcinomas (37), and hepatocarcinomas 
(38). Thus, the source of ETP in the tumor microenvironment 
may be heterogeneous, with signals cooperatively influencing 
cancer cell behavior through paracrine and autocrine pathways. 
Nevertheless, stromal adipocytes represent a prominent source 
for COL6 in the mammary tumor microenvironment (Supple-
mental Figure 10A). However, the detailed mechanisms underly-
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small-animal anesthesia system (EZ Systems). At the end of experiments, each 
organ was collected and imaged for signal intensity with the Odyssey scanner. 
Quantified values were normalized to the total area of each organ.
Histological analysis. Formalin-fixed paraffin-embedded tissue sections 
were used for immunohistochemistry. Deparaffinized tissue slides were 
stained with the primary antibodies shown in Supplemental Methods. 
Staining for functional blood vessels and hypoxic lesions as well as whole-
mount staining of mammary glands were followed as described previously 
(52). TUNEL assays were performed according to the manufacturer’s pro-
tocol (Trevigen Inc.). Masson’s Trichrome C and H&E staining were per-
formed by J. Shelton (University of Texas Southwestern Medical Center, 
Dallas, Texas, USA). Deidentified human tumor samples were obtained 
from the University of Texas Southwestern Tissue Resource.
Primary culture of mammary cancer cells and implantation. Isolation of mam-
mary epithelial cancer cells and implantation procedures were as previous-
ly described (52). Tumor growth was monitored once weekly beginning 2 
weeks after implantation.
In vitro cell migration assay. Thioglycollate-elicited macrophages or MS-1 
in serum-free media were loaded into the upper chamber of a Transwell 
plate (8 μm pore size; Costar). As chemoattractants, ETP or the indicated 
cancer cells were added to the bottom chamber with DMEM containing 
2% FBS. 18 hours later, cells on the underside of the membrane were fixed 
with 10% formalin, stained with hematoxylin, and counted. Images were 
acquired using the Nikon Cool Scope (Nikon).
Statistics. Data are presented as mean ± SEM. Data were analyzed by 
2-way ANOVA followed by Newman-Keuls multiple comparison test or by 
2-tailed Student’s t test, as appropriate, with GraphPad Prism version 5 
software. A P value less than 0.05 was considered statistically significant.
Study approval. This study was carried out in strict accordance with the 
recommendations of the NIH Guide for the Care and Use of Laboratory Ani-
mals. All animal experiments were approved by the Institutional Animal 
Care and Research Advisory Committee at the University of Texas South-
western Medical Center (protocol no. 2010-0006). All efforts were made to 
minimize animal suffering.
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although there is no further evidence whether these MMPs cleave 
ETP. Base on the fact that most cancer cells express high levels of 
MMPs associated with tumor growth and metastasis (47), it is like-
ly that there are abundant sources for ETP cleavage activity within 
the tumor microenvironment. The identification of the critical 
protease involved in ETP processing may offer a new approach 
to curbing growth by pharmacologically inhibiting this step. Our 
findings unveiled an important role of the adipocyte as an active 
component of the tumor stroma that actively interacts with cancer 
cells and a number of other relevant local cell types. Our data high-
light that an adipocyte-derived ECM cleavage product actively con-
tributed toward the remodeling of the tumor microenvironment by 
enabling the progression of tumor growth and metastasis through 
enhancement of the EMT process and subsequent chemotaxis of 
endothelial cells and macrophages. In many aspects, the deposition 
of ECM components, such as ETP in the tumor stroma, resembles a 
wound-healing process, as this involves the recruitment and stimu-
lation of immune cells, endothelial cells, and fibroblasts during the 
wound repair process. However, unlike during the wound-healing 
process, ETP prompts cancer cells to sustain mesenchymal cell–
like traits and activates fibroblasts in the tumor stroma, drasti-
cally increasing local fibrosis and eventually enhancing metastatic 
growth. Our findings have further implications for several tissues 
that have an associated pathological fibrotic component, such as 
the liver (48), cartilage (49), lung (50), and heart (51); COL6 expres-
sion has been documented in all these tissues. Future efforts tar-
geted toward ETP neutralization in various pathological settings 
should establish whether this approach is a viable antifibrotic 
strategy that is generally beneficial, not only in the setting of tumor 
progression and metastasis, but also during normal AT expansion.
Methods
See Supplemental Methods and complete unedited blots in the supple-
mental material.
Mice. See Supplemental Methods for detailed information on the mice 
used herein. All experiments were conducted using littermate-controlled 
female mice. All animals used in this study were in a pure FVB background.
Tumor imaging. FP635/PyMT mice or cancer cells isolated from tumors 
from FP635/PyMT mice were imaged with an IVIS scanner (Caliper Life-
sciences), and the signal intensity was analyzed with Living Image version 
3.2 (Caliper Lifesciences). See Supplemental Methods for conventional 
analyses of tumor growth and metastasis.
ETP-specific polyclonal and monoclonal antibodies. ETP-GST fusion proteins 
for both mouse and human ETPs were purified from bacteria and used as 
antigens for polyclonal antibodies (Covance). For monoclonal antibody 
generation, native ETP was purified by gel filtration chromatography (GE 
Healthcare) from conditioned media of a mouse ETP-overexpressing HEK-
293 stable cell line. See Figure 2A for ETP amino acid sequences.
Quantitative RT-PCR. Total RNA was isolated using the RNeasy kit (Qia-
gen) following tissue homogenization in TRIzol (Invitrogen). Total RNA 
(1 μg) was reverse transcribed with SuperScript III reverse transcriptase 
(Invitrogen). Quantitative real-time PCR (qRT-PCR) was performed using 
Roche Lightcycler 480. Primer sequences used in this study have been 
described previously (33, 34, 52).
Analysis of ETP homing. The homing of ETP in circulation was determined by 
injecting fluorescently labeled ETP into tail veins. ETP and IgGs were labeled 
with IRDye800 CW NHS Ester (Licor Bioscience) at a 1:1 molar ratio (dye/
protein), according to the manufacturer’s instructions. Whole-body fluores-
cence images were collected on the Odyssey scanner (Licor Bioscience). All 
scans were performed under anesthesia (Aerrane) using an EZ-2000 Microflex 
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